Apollo economist warns: AI bubble now bigger than 1990s tech mania
Versant Venture Capital entities reported selling shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ), for a total of $10.1 million. The sales occurred at prices ranging from $29.95 to $30.35, near the current trading price of $29.94. The stock has shown remarkable strength, gaining over 65% in the past year according to InvestingPro data.
On June 18, 2025, Versant Venture Capital VII, L.P. sold 100,000 shares at $29.95 per share. Then, on June 20, 2025, Versant Venture Capital VII, L.P. sold 100,877 shares at $30.35 per share. On the same day, Versant Venture Capital VI, L.P. sold 133,924 shares at $30.25 per share. Despite these sales, LENZ maintains a strong financial position with more cash than debt and a healthy current ratio of 23.09.
Following these transactions, Versant Venture Capital VII, L.P. indirectly holds 1,047,912 shares, Versant Venture Capital VI, L.P. directly holds 1,967,275 shares and Versant Vantage II, L.P. indirectly holds 842,162 shares. With analyst price targets ranging from $36 to $60, investors can access comprehensive valuation analysis and 7 additional key insights through InvestingPro’s detailed research reports.
In other recent news, LENZ Therapeutics reported its financial results for the first quarter of 2025, revealing a net loss per share of $0.53. Despite this, the company maintains a strong cash position of $194.1 million, highlighting its focus on advancing its presbyopia treatment, LNZ100, with a PDUFA target date set for August 8, 2025. Additionally, LENZ Therapeutics has entered into an exclusive licensing agreement with Lotus Pharmaceutical for the commercialization of LNZ100 in the Republic of Korea and select Southeast Asian countries, potentially earning up to $125 million in payments. Citi analysts reiterated a Buy rating on LENZ Therapeutics with a $45 price target, citing the potential FDA approval of LNZ100 as a significant milestone. The analysts expressed confidence in the approval process, noting the product’s established safety profile and previous marketing in Europe. In a recent stockholder meeting, the company elected new directors and ratified Ernst & Young LLP as its independent auditor. These developments underscore LENZ Therapeutics’ strategic efforts to expand its market presence and prepare for the commercialization of its innovative treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.